NGM Bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $122M
Overview
A clinical-stage biotech developing novel biologics for liver, metabolic, and retinal diseases, and cancer.
Metabolic DiseasesOncologyOphthalmology
Technology Platform
A biology-driven discovery platform that integrates human genetics, molecular profiling, and protein engineering to identify and develop novel biologic therapeutics.
Funding History
1Total raised:$122M
PIPE$122M
Opportunities
Aldafermin could capture a significant share of the large and growing MASH market if it demonstrates strong Phase 3 efficacy.
Risk Factors
Clinical failure of aldafermin would severely impact valuation, given its status as the lead program in a crowded field.
Competitive Landscape
Faces intense competition in MASH from large pharma (e.g., Madrigal, Novo Nordisk) and other biotechs, requiring differentiation on efficacy and safety.